Preclinical Toxicity Screening of Intrathecal Oxytocin in Rats and Dogs

Tony L. Yaksh, Ph.D., Shotaro Hobo, M.D., Christopher Peters, Ph.D., Kent G. Osborn, D.V.M., Ph.D., Philip J. Richter, Jr., D.V.M., Ph.D., D.A.C.L.A.M., Steven S. Rossi, Ph.D., Marjorie R. Grafe, M.D., Ph.D., James C. Eisenach, M.D.

ABSTRACT

Background: Anatomic, physiologic, and behavioral studies in animals suggest that spinally released oxytocin should produce analgesia in humans and may also protect from chronic pain after injury. In this article, the authors report preclinical toxicity screening of oxytocin for intrathecal delivery.

Methods: Intrathecal oxytocin, 11 μg (6 U) or vehicle, was injected intrathecally in 24 rats, followed by frequent behavioral assessment and histologic examination of spinal contents 2 or 14 days after injection. In three dogs, a range of intrathecal oxytocin doses (18 to 550 μg in 0.5 ml) was injected followed by physiologic, biochemical, and behavioral assessments. Ten dogs were then randomized to receive five daily injections of intrathecal oxytocin, 550 μg in 0.5 ml, or vehicle with similar assessments and, necropsy and histologic analysis were conducted 2 days later.

Results: In rats, intrathecal oxytocin resulted in transient scratching and itching behaviors, without other differences from vehicle. There was no behavioral, gross anatomic, or histologic evidence of neurotoxicity. Dose ranging in dogs suggested mild effects on motor tone, blood pressure, and heart rate at the 550 μg dose. Repeated boluses in dogs did not produce behavioral, biochemical, neurologial, gross anatomic, or histologic evidence of neurotoxicity.

Conclusions: Substances, including natural neurotransmitters, may be toxic when administered in pharmacologic doses in the spinal cord. This preclinical toxicity screen in two species suggests that bolus injections of oxytocin in concentrations up to 1,100 μg/ml are unlikely to cause neurotoxicity. The authors also support cautious clinical application of intrathecal oxytocin under regulatory supervision. (ANESTHESIOLOGY 2014; 120:951-61)

The nonapeptide oxytocin, contained in neurons of the hypothalamic paraventricular nucleus, is released from the pituitary into the blood where it induces uterine contractions, protects the fetal brain during delivery, and facilitates lactation.1 Importantly, circulating oxytocin re-enters the central nervous system to an exceedingly limited extent.2 Other neurons in the paraventricular nucleus project within the central nervous system to alter many aspects of behavior, especially related to social engagement and bonding, in both sexes across the life cycle.3

We recently observed that chronic pain from childbirth, including cesarean delivery, is remarkably rare3 and that recovery from hypersensitivity from peripheral nerve injury in rats is accelerated when injury occurs surrounding the time of delivery.4 This protective effect in the peripartum period is reversed by intrathecally administered oxytocin receptor antagonists,4 consistent with a role of spinal oxytocin in accelerating recovery from pain after injury. This hypothesis is consistent with recent anatomic and physiologic studies. As such, oxytocin-containing paraventricular nucleus neurons project to the superficial dorsal horn of the spinal cord,5,6 and cerebrospinal fluid (CSF) oxytocin concentrations increase in lumbar CSF in women during labor.7 Paraventricular nucleus stimulation temporarily

What We Already Know about This Topic

- Oxytocin, a hormone involved in labor, maternal bonding, and lactation, can also stimulate receptors in the spinal cord
- Spinal administration of oxytocin produces analgesia in experimental animals

What This Article Tells Us That Is New

- As a safety screen, oxytocin was administered repeatedly into the lumbar spinal space of dogs and rats
- Lack of neurotoxicity from these studies paves the way for future studies in humans under federal regulatory guidance
reverses spinal neuronal and behavioral hypersensitivity from nerve injury in a manner reversed by oxytocin receptor antagonists. These effects are mimicked by intrathecal injection of oxytocin itself. Oxytocin acts in the spinal cord to inhibit nociceptive neurotransmission in part by stimulating γ-amino-butyric acid release and increasing potassium channel conductance in lamina II neurons. The above observations suggest that intrathecal oxytocin may treat established neuropathic pain and potentially prevent chronic pain after surgery.

These studies provide the rationale for clinical investigation of intrathecal oxytocin for the prevention and treatment of pain but do not provide evidence of safety. Administering large doses of oxytocin systemically to achieve central nervous system penetration is not feasible, given QT prolongation and hypotension that would ensue. Oxytocin is an endogenously produced compound not implicated to cause cell necrosis, apoptosis, or inflammation, but other endogenously produced peptides do cause neurotoxicity when administered intrathecally as does stimulation of some spinal neurotransmitter receptors by intrathecally administered agonists. In addition, although oxytocin has a higher affinity for oxytocin receptors than vasopressin receptors, its agonist activity at higher concentrations on vasopressin receptors could lead to spinal cord ischemia locally or hypertension and hyponatremia by systemic absorption. For these reasons, formal preclinical toxicity testing is mandatory. In this study, we report preclinical toxicity of intrathecal oxytocin in validated approaches using rats and dogs, focusing on local effects, physiologic actions, and spinal histopathology as guidance for subsequent clinical introduction for investigation.

Materials and Methods

The studies were approved by the Animal Care and Use Committee at the University of California, San Diego, San Diego, California, for dog studies and Wake Forest School of Medicine, Winston-Salem, North Carolina, for rat studies.

Drug

Because marketed formulations of oxytocin contain neurotoxic preservatives and are only available in low concentrations, we obtained USP oxytocin powder from GRINDEKS (Riga, Latvia), a Food and Drug Administration–certified facility which manufactures oxytocin for clinical use. It was manufactured according to Good Manufacturing Practices guidelines. Information on synthesis methods, composition, and other characteristics that define this powder are maintained by GRINDEKS and filed with the Food and Drug Administration.

Rat Studies

Twenty-four male Sprague–Dawley rats (Harlan Industries, Indianapolis, IN), weighing 238 to 306 g, were studied. Animals were maintained in individual cages with ad libitum food and water on a 12-h light/dark cycle.

Drug Administration. After acclimation to the laboratory and testing procedures, animals were briefly anesthetized with inhalational isoflurane, and a direct lumbar puncture was performed between the L5 and L6 vertebrae using a 30-gauge, half-inch needle which is at the level of the cauda equina. Previous dye distribution studies in rats have demonstrated that a 10-μl injection volume spreads to above the L3 to L4 level after lumbar puncture at this site. Proper needle location was identified by a brief tail flick. In control experiments using motor block from injection of lidocaine as a measure of success, the success rate in our laboratory exceeds 95%. After lumbar puncture, rats received an injection of 10 μl of sterile saline alone, or containing 11 μg (6 U) of oxytocin (n = 12 per group). Oxytocin was dissolved in sterile saline and terminally sterilized by passage through a sterile 0.22 μm filter. The dose and concentration of oxytocin used and timing of experiments were determined in consultation with Food and Drug Administration staff, and the concentration used was the same as that used in the study in beagle dogs.

Behavioral Assessment. Each animal received a single-bolus injection. Half of the animals (n = 6 with saline and n = 6 with oxytocin injection) were sacrificed 2 days after injection and the other half (n = 6 with saline and n = 6 with oxytocin injection) were sacrificed 14 days after injection. Arousal, motor coordination, and motor tone were assessed in all animals 0.5, 1, 2, and 4 h after intrathecal injection, then daily until 2 days after treatment. These assessments were also made at 7 and 14 days after treatment in the longer observation group. Arousal scores were assessed on a seven-point scale as previously described, ranging from −3 (comatose) to +3 (maximal excitation). Motor coordination was evaluated using a four-point scale, ranging from normal symmetric posture (0) to lack of righting response (−3) and motor tone using a seven-point scale ranging from extreme rigidity (−3) to normal (0) to postural tone (3). In addition, because intrathecal oxytocin causes scratching behavior in mice, we also assessed grooming and scratching behavior, summing episodes of these behaviors during a 2-min period.

Anatomic Assessment. On completion of the study 2 or 14 days after intrathecal injection, animals were deeply anesthetized with pentobarbital. The left ventricle was cannulated and perfused with phosphate buffer, followed by 4% paraformaldehyde. After removal of the vertebral column, the spinal cords were removed. After fixation in formalin, blocks were embedded in paraffin, sectioned at 10-μm thickness, and stained with hematoxylin–eosin for general examination and Luxol fast blue for myelin. Coded sections from the lower lumbar region of the spinal cord (L4 to L6) rostral to the injection site were examined by an investigator, who was blinded to drug-treatment group, in random order for all animals. Particular attention was given to the presence...
or absence of inflammation and demyelination in the spinal cord parenchyma.

**Dog Studies**

Thirteen adult, destination bred beagles (Marshall Farms USA, North Rose, NY) were studied. Animals were housed in a dedicated facility with fluorescent lighting on a daily 12-h light/dark cycle, with free access to dry dog food and water. A dose-ranging study was performed in three male dogs followed by a repeated bolus study in five male and five female dogs.

**Dose-ranging Study**

**Surgery.** Food was withheld on the evening before surgery. An intrathecal catheter was inserted as previously described.\(^{22}\) Sulfamethoxazole–trimethoprim (240 mg tablet, 15 to 25 mg/kg, oral, twice daily) was given 48 h before surgery and for 48 h after surgery. After sedation with xylazine, 1.5 mg/kg, intramuscular, anesthesia was induced with mask isoflurane, the trachea intubated, and anesthesia maintained with 1.0 to 2.0% isoflurane and 60% N\(_2\)O/40% O\(_2\) with spontaneous ventilation. Animals were continuously monitored for oxygen saturation, inspired and end-tidal values of isoflurane, carbon dioxide, nitrous oxide, heart, and respiratory rate. After skin preparation with chlorhexadine, a midline neck incision and dissection were performed, the cisterna magna exposed, a 1- to 2-mm incision made in the dura, and a sterilized polyurethane intrathecal catheter (0.61 mm outside diameter, fabricated at ReCathCo Inc., Allison Park, PA) inserted and passed caudally a distance of approximately 40 cm. Confirmation of appropriate catheter placement in the intrathecal space was judged by the free outflow of CSF. The catheter was then tunneled subcutaneously and caudally to exit at the midline scapular region.

Dexamethasone sodium phosphate (0.25 mg/kg, intramuscular) was administered just after catheter placement, and butorphanol tartrate, 0.04 mg/kg, intramuscular, and carprofen, 4.5 mg/kg, subcutaneous, were administered to relieve postoperative pain and inflammation.

**Drug Administration.** Each animal received a series of intrathecal injections of escalating doses of oxytocin (18, 55, 180, and 550 μg, corresponding to 10, 30, 100, and 300 U, in an 0.5 ml volume followed by 0.3 ml saline flush) beginning 3 days after intrathecal catheter insertion and with doses separated by 2 to 5 days. Based on tolerability results, one of the animals then received 550 μg/0.5 ml of intrathecal dose at approximately 24-h intervals for 5 days.

**Behavioral, Physiologic, and Biochemical Measures.** Levels of arousal, muscle tone, and coordination were assessed as previously described\(^ {26}\) daily beginning 17 days before the first intrathecal dose and at 10, 20, 30, 60, 120, and 240 min after each dose and daily in between dosing. Animals were also assessed for general behavior, appetite, temperature, and defecation and urination on a daily basis. Blood pressure and heart rate were measured noninvasively and respiratory rate by observation at the same times as the behavioral assessments. Before surgery, blood samples were taken for standard hematology and clinical chemistry testing, performed by a clinical laboratory service.

**Plasma Oxytocin Sampling and Analysis.** Cephalic vein blood samples (approximately 2 ml) were collected by venipuncture into EDTA tubes before intrathecal injection and at the same time as behavioral assessments. Blood samples were placed on wet ice, centrifuged, and the plasma stored frozen at −20° ± 10°C until assayed. Oxytocin concentrations were measured by enzyme-linked immunosorbent assay using a commercially available kit (Oxytocin Enzyme Immunoassay Kit; Assay Designs, Ann Arbor, MI), using the methods described in the commercial kit.

**Repeated Bolus Study**

Unless otherwise indicated, surgery and behavioral, physiologic, and biochemical measures were identical to the dose-ranging study.

**Drug Administration.** Animals were randomized, using an unbalanced design to receive daily intrathecal injections of vehicle (two males, two females) or oxytocin (three males, three females) for 5 consecutive days. Based on the dose-ranging study, the daily oxytocin dose was 550 μg delivered in 0.5 ml.

**Timing of Assessments.** Behavioral assessment, blood pressure, and heart and respiratory rate were determined before surgery and 15 min before and 60 min after each intrathecal dose. Neurologic examinations were performed by a veterinarian (P.J.R.) before placement of the intrathecal catheter, after intrathecal catheter placement but before initiation of the dosing regimen, and at the end of the dosing regimen. Blood was sampled for oxytocin analysis 60 min after the first and fifth intrathecal dose. In addition, blood and cisternal CSF were sampled before surgery and at necropsy for routine hematology and chemistry.

**Anatomic Assessment.** Two days after the last intrathecal injection, the dog was sedated with sodium pentobarbital (35 to 50 mg/kg), the chest was opened, the aorta catheterized, and blood was cleared by perfusion with approximately 4 l of 0.9% saline, followed by approximately 4 l of 10% formalin. The dura of the spinal canal was then exposed by laminectomy. Dye was injected through the catheter to visualize the catheter tip position and its spatial relationship to the cord. The cord was then cut into four sections: cervical, thoracic, lumbar (with catheter tip region), and lumbar, below the catheter tip region, removed and submitted for microscopic examination by a neuropathologist (M.R.G.). Gross necropsy evaluation was performed by a veterinarian (K.G.O.), including examination of skin, muscle, sciatic nerve, eye, ear, salivary glands and associated lymph nodes, oral cavity, tongue, larynx, trachea, bronchi, lungs, parabronchial lymph nodes, heart, thyroid, parathyroid, adrenal, pituitary, brain, kidneys, urinary bladder, reproductive system, liver, pancreas, spleen, esophagus, stomach, small and large intestine, and mesenteric lymph nodes. Tissues sampled and placed in...
formalin from all animals included spinal cord, dorsal root ganglia, eye (retina), sciatic nerve, cerebral cortex (dorsal, at midpoint between rostral and caudal poles), and brainstem. Sections of spinal cord with associated dura and dorsal root ganglion were examined by a neuropathologist from four levels (cervical, thoracic, upper lumbar, and lumbar). Hematoxylin and eosin–stained sections for each level and glial fibrillary acidic protein and Luxol fast blue–stained sections of the upper lumbar block were examined for evidence of spinal cord compression, reactive gliosis, demyelination, inflammation, fibrosis, and any other injury. Histopathology was graded for each level based on the degree of inflammation and fibrosis. In brief, the degree of pathology (based on chronic and/or acute inflammation and fibrosis) was graded as 0 (normal), mild (1), moderate (2), or severe (3), as previously described.26 The veterinarians and neuropathologist were blinded as to treatment group.

**Statistical Analysis**

Data are presented as mean ± SD or median [25th to 75th percentile] as appropriate. Only summary statistics are shown for the dose-ranging study in three animals. Repeated observations were analyzed using a repeated-measures three-way ANOVA followed by a protected post hoc testing. For single measures, the groups were compared by unprotected, two-way Student $t$ tests. $P$ value less than 0.05 was considered significant.

**Results**

**Rat Study**

Spinal injections were well tolerated by all rats, and none of the animals exhibited pain behavior after injection of the drug. Intrathecal injection of oxytocin, but not vehicle, produced grooming and scratching behavior, lasting less than 1 h ($P < 0.001$; fig. 1). Neither saline nor oxytocin produced changes in motor coordination or tone (all scores were normal at all times after injection). Arousal scores were increased in 2 of 12 animals receiving oxytocin (to 1 = intense grooming and mild hyperactivity) 30 min after injection, but all other scores were normal at all times after injection. All rats survived treatments as scheduled and there were no abnormal behaviors observed on days of testing or thereafter. All animals showed normal gait and appeared well groomed throughout the study period. Body weight and weight gain did not differ between groups (data not shown). At the end of study, visual inspection of the spinal cord tissue and meninges revealed no gross abnormalities. Perfusion was adequate in all animals. Histologic examination revealed no signs of inflammation or necrosis in any of the treatment groups based on hematoxylin and eosin staining (fig. 2, A and B) or white matter vacuolization or demyelination based on Luxol fast blue staining (fig. 2, C and D).

**Dog Dose-ranging Study**

No untoward effects on behavior or health were noted during the course of the study. Arousal, muscle tone, and coordination were all within normal range. No clear pattern of intrathecal oxytocin on blood pressure emerged although there was a large effect size of reduced blood pressure (−28%) 10 to 20 min after injection of the lowest dose and a modest effect size of increased blood pressure (+27%) 20 to 60 min after injection of the largest dose (fig. 3A). Heart rate decreased 20 to 50% with a nadir 10 to 20 min after intrathecal injection in a dose-independent manner (fig. 3B). Plasma concentrations of oxytocin increased from a baseline of approximately 100 pg/ml in a dose-dependent manner with a peak at 20 to 30 min after intrathecal injection (fig. 4). The animal receiving 5-day repeated bolus injections demonstrated agitation during injection on the third, fourth, and fifth days and hindlimb stiffness in posture 10 to 60 min after injection after the fourth and fifth days Mean arterial blood pressure increased 10 to 30% and heart rate decreased 10 to 45% 1 h after the daily injections. Preinjection plasma oxytocin was numerically greater before the last injection (300 pg/ml) than the first (180 pg/ml), with peak concentrations of approximately 3,000 pg/ml 20 min after injection on both days.

**Dog-repeated Bolus Study**

All animals survived to sacrifice. No untoward effects on general behavior, health, or body weight were noted during the course of the study. Detailed neurological examinations after catheter placement and at sacrifice were unremarkable with the exception of two dogs, both in the intrathecal saline group, which exhibited a very mild hypermetria in the hind limbs after intrathecal catheter placement. The magnitude of the change was judged to be modest and acceptable to permit entry of the dogs in the study. Behavioral scores for arousal, muscle tone, and coordination were assessed over a range of 0 to ±3 as previously described23 during the interval before and through 240 min after each of the five intrathecal injections. The sum of the behavioral scores for all of the vehicle dogs ($N = 4$) was 0, 0, and 0, and for the oxytocin dogs ($N = 6$) was 0, 2, and 0 for each of the three measures, respectively, indicating no treatment-related changes after multiple intrathecal deliveries of oxytocin.
Body temperatures were within normal range of 37.2° to 39.0°C before and at 60 min after injection. Respiratory rates were within normal range of 18 to 34 breaths/min before and at 60 min after injection without difference between groups. Groups did not differ in mean arterial pressure before or 1 h after each injection (fig. 5A). In contrast, the groups differed with respect to heart rate (fig. 5B). In the saline group, there was no effect of day of injection or injection on heart rate. In contrast, in the oxytocin effect, there was a significant effect of heart rate with injection (\(P = 0.013\)) but not an effect of day or interaction between injection and day. This can be exemplified by collapsing the effect of injection on all Fig. 2. Histological assessment of lumbar rat spinal cord 14 days after a single-bolus intrathecal injection of saline (A, C) or 11 \(\mu\)g of oxytocin (B, D). Histological examination revealed no signs of inflammation or necrosis in either treatment groups based on hematoxylin and eosin staining (A, B) or white matter vacuolization/demyelination based on Luxol fast blue staining (C, D). Some spinal cord tissue blocks were marked in the ventral horn with ink (arrowhead) for identification purposes after histological processing. Scale bar in (D) = 500 \(\mu\)m.

Fig. 3. (A) Mean arterial blood pressure and (B) heart rate after intrathecal injection, at time 0, of oxytocin in 0.5ml in three dogs. Data are median.

Fig. 4. Plasma oxytocin concentrations after intrathecal injection, at time 0, of oxytocin in three dogs. Data are median.
days, with heart rate 111 ± 21 beats/min before and 111 ± 24 beats/min after injection after saline treatment compared with 100 ± 27 beats/min before and 73 ± 33 beats/min after injection after oxytocin treatment.

There were no clinically significant differences between treatment groups in pre- and posttreatment chemistries or hematology in CSF or blood, including sodium concentration (data not shown). There was a large increase in CSF protein concentration, as previously observed in this intrathecal catheter preparation, from 19 ± 11 mg/dl before catheterization to 94 ± 47 mg/dl at necropsy in the oxytocin group and from 16 ± 1 to 101 ± 27 mg/dl in the saline group, respectively. One animal from each group had leukocyte count increased in CSF at the end of treatment without local or systemic evidence of infection. Oxytocin concentrations in plasma 1 h postinjection on day 0 and day 4 were not different in animals receiving saline (1,649 ± 1,503 and 1,188 ± 961 pg/ml, respectively) or in those receiving oxytocin (19,894 ± 6,316 and 27,260 ± 5,046 pg/ml, respectively).

At necropsy, organs and tissues were grossly normal, with the exception of small foci on the subcapsular and cut surface of both kidneys, consistent with minimal bilateral infarcts (oxytocin animal), and mild multifocal petechial in all lung lobes (saline animal).

Spinal histopathology revealed no systematic change in any treatment group, when the oxytocin-treatment group was specifically compared with the saline-treatment group (table 1). Comparison of pathology scores across spinal block C (catheter tip, where drug concentrations are considered to be highest) revealed no statistical difference between oxytocin- and vehicle-treated animals. Comparisons of pathology scores were made across treatments for the A, B, and D blocks, and similarly, no difference was noted (table 2). Furthermore, comparisons between A, B, D versus C blocks revealed no trend for differences between those blocks which were distal to the catheter tip or proximal to the catheter tip, where drug concentration would be highest (table 2). Representative images are presented in figure 6.

Most animals showed focal, minimal thickening of the dura with a mild fibroblast proliferation and macrophage infiltration, consistent with a reaction to the catheter. Most had a mild inflammatory infiltrate in dura (focal) and/or arachnoid (focal or diffuse). The inflammatory infiltrates were variable mixtures of macrophages, lymphocytes, plasma cells, and neutrophils (table 1). Three animals had leptomeningeal inflammation in the section of medulla (two in oxytocin and one in saline group); one of these also had leptomeningeal inflammation in the section of neocortex (saline). There was no inflammation in the spinal cord parenchyma. Several animals had focal, mild compression of the outer surface of the spinal cord in the region of the catheter, but none of these showed any evidence of parenchymal damage to the spinal cord by hematoxylin and eosin, glial fibrillary acidic protein, or myelin stains. Two animals had minimal gliosis in the spinal cord gray matter, seen only with glial fibrillary acidic protein stains. This did not correlate with the presence or degree of spinal cord compression, meningeal inflammation, or other changes. Sections stained with Luxol fast blue showed no evidence of demyelination (fig. 7). Sections of peripheral nerve, dorsal root ganglia, retina, and skeletal muscle were unremarkable.

**Discussion**

Preclinical assessment for clinical introduction of an agent for intrathecal administration includes effects at the site of injection and those distant from injection, whether due to systemic absorption or cephalad transport in CSF. The current study showed no evidence of drug-related tissue toxicity, as measured by neurologic assessment, gross necropsy, histopathology examination, and CSF chemistry and hematology, in two species: the rat and the dog. In the rat, both acute (2 day) and chronic (14 day) histopathology was screened after a single intrathecal injection. In the dog, multiple intrathecal injections at 24-h intervals revealed no cumulative behavioral toxicity or histopathologic toxicity, including measures of focal astrocyte activation. Hemodynamic changes were consistent with effects on oxytocin and vasopressin receptors,
which may be dose limiting in clinical application. The robustness and adequacy of this preclinical evaluation and its implications for clinical introduction deserve comment.

Intrathecal Dosing and Drug Tissue Exposure

As the intrathecal space represents a relatively static fluid environment,28 the occurrence of local adverse events is considered to reflect primarily the local concentrations to which the adjacent tissues (spinal cord and meninges) are exposed and the duration of that exposure.29,30 With regard to concentration, clinicians typically measure intrathecal injections in terms of dose, but for local toxicity, both drug concentration and duration of exposure are considered to be of particular importance.30,31 The therapeutic intrathecal oxytocin dose in dogs is unknown, but in rats, it is approximately 0.1 to 1.0 μg,32 administered in a volume of 10 μl, or a concentration of 10 to 100 μg/μl. The highest concentration used in the current evaluation was 1,100 μg/ml (approximately 600 U/ml) and was chosen in part because of mild behavioral and hemodynamic effects in the dog dose-ranging study.

A further consideration regarding the local tissue drug exposure after bolus delivery reflects the local dilution of the intrathecal injectate and this dilution factor is proportional to the local volume in to which the drug is delivered. We have previously noted that the local volume at the cord level is conservatively proportional to the circumference of the cord which in humans and dogs represents a ratio of 3:1. Thus, for a given dose and volume, the human displays a dilution which is approximately three times that observed after lumbar intrathecal delivery in the dog (see the study by Manning et al.19). In the current case, we suggested that based on local dilution in the two spinal spaces, equivalent estimated concentrations would require 3,300 μg/ml in the human to

Table 1. Summary of Spinal Cord Pathology in Dogs

<table>
<thead>
<tr>
<th>Animal</th>
<th>Test/Control Article</th>
<th>Score C</th>
<th>Score A + B + C + D</th>
<th>A Cervical + DRG</th>
<th>B Thoracic + DRG</th>
<th>C Lumbar + DRG</th>
<th>D Lumbar + DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>543 2774</td>
<td>Oxytocin</td>
<td>0</td>
<td>0.75</td>
<td>Fibroblasts/ macrophages</td>
<td>Unremarkable</td>
<td>Unremarkable</td>
<td>Unremarkable</td>
</tr>
<tr>
<td>502 8604*</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>3.25</td>
<td>Compressed/ sparse inflammation</td>
<td>Fibroblasts/ macrophages/ sparse inflammation</td>
<td>Minimal fibroblasts</td>
<td>Minimal fibroblasts/ macrophages</td>
</tr>
<tr>
<td>542 9935†</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>3.75</td>
<td>Unremarkable</td>
<td>Fibroblasts/ macrophages</td>
<td>Lymphocytes/ plasma cells/ neutrophils/ fibroblasts</td>
<td>Fibroblasts/ macrophages</td>
</tr>
<tr>
<td>543 4297†</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>1.5</td>
<td>Unremarkable</td>
<td>Unremarkable</td>
<td>Mild thickening/ fibroblasts/ macrophages</td>
<td>Fibroblasts/ macrophages/ monocytes</td>
</tr>
<tr>
<td>501 5219†</td>
<td>Saline</td>
<td>0.75</td>
<td>3.25</td>
<td>Thickening/ fibroblasts/ macrophage</td>
<td>Fibroblasts/ macrophages</td>
<td>Focal thickening/ fibroblasts</td>
<td>Fibroblasts/ macrophages</td>
</tr>
<tr>
<td>501 5014</td>
<td>Oxytocin</td>
<td>1</td>
<td>2.75</td>
<td>Focal thickening/ fibroblasts</td>
<td>Unremarkable</td>
<td>Focal thickening/ fibroblasts/ rare clusters macrophages/ lymphocytes</td>
<td>Multifocal fibroblasts/ macrophages/</td>
</tr>
<tr>
<td>503 7565†</td>
<td>Oxytocin</td>
<td>1.25</td>
<td>5.25</td>
<td>Neutrophils/ macrophage/ lymphocytes</td>
<td>Focal thickening/</td>
<td>Neutrophils/ macrophages/ lymphocytes/ neutrophils</td>
<td>Lymphocytes/ plasma cells</td>
</tr>
<tr>
<td>501 8501</td>
<td>Saline</td>
<td>2</td>
<td>6</td>
<td>Thickening/ compressed/ fibroblasts/ macrophage</td>
<td>Compressed/ fibroblasts/ macrophages</td>
<td>Lymphocytes/ plasma cells/ macrophages</td>
<td>Lymphocytes/ plasma cells/ macrophages</td>
</tr>
<tr>
<td>543 0194</td>
<td>Oxytocin</td>
<td>2.25</td>
<td>10.25</td>
<td>Mild thickening/ neutrophils/ fibroblasts</td>
<td>Mild compression/ fibroblasts/ macrophages</td>
<td>Mild thickening/ neutrophils/ fibroblasts</td>
<td>Mild thickening/ neutrophils/ fibroblasts</td>
</tr>
<tr>
<td>502 9988</td>
<td>Saline</td>
<td>3</td>
<td>11</td>
<td>Thickening/ compressed/ fibroblasts/ macrophage neutrophils/ lymphocytes</td>
<td>Compressed/ fibroblasts/ macrophages neutrophils/ lymphocytes</td>
<td>Macrophages neutrophils/ lymphocytes/ plasma cells/</td>
<td>Macrophages neutrophils/ lymphocytes/ plasma cells/</td>
</tr>
</tbody>
</table>

* Representative glial fibrillary acidic protein; † Representative hematoxylin and eosin.

DRG = dorsal root ganglion.
approach the same concentrations that were well tolerated in the dog. Finally, we mimicked the planned clinical exposure of a bolus intrathecal injection (rather than by an infusion delivery), and to increase the robustness of the neurotoxicity exposure by repeated daily bolus dosing in the dog.

**Projected Safety of Intrathecal Oxytocin in Humans**

In humans, we have estimated that the projected maximum intrathecal dose should not exceed 150 μg/3 ml (50 μg/μl), given concerns of systemic side effects. Given these three parameters defining the robustness of the exposure, we would note that the projected human bolus dose would thus be 1 of 22 to 1 of 66 of the dose readily tolerated in dogs with and without consideration respectively of a dilution factor. Furthermore, in contrast to the projected single-dose exposure for human, the current work shows that even five repeated injections of this dose/concentration were without deleterious reactions when assessed by function and systemactic spinal histopathology, even at the site of drug delivery where concentrations and exposure would be maximum.

Importantly, the current study provides evidence for safety at these concentrations and dosing regimens only, and other studies would be necessary to support sustained treatment or intrathecal infusion. In addition, whether perineural or epidural administration of oxytocin is safe was not assessed by these studies.

**Spinal Inflammatory Responses to the Catheter**

We note parenthetically that lack of inflammation in spinal cord histopathology in the current rodent study is in contrast to our previous work with toxicity assessment of neostigmine, adenosine, and ketorolac, in which inflammation and white matter vacuolation were present in drug- and vehicle-treated animals. This was likely due to the presence of the spinal catheter in these other studies, as there was a rim of inflammatory cells surrounding the catheter track and inflammation of tissue adjacent to the track. We did not insert an intrathecal catheter in the current rodent studies of oxytocin, and did not observe such histopathologic changes. In the dog studies, we did observe minor changes after catheterization, consistent with previous reports. The transient scratching and grooming behavior observed in rats parallels that observed in mice and is consistent with oxytocin action on vasopressin 1a receptors in the spinal cord of rodents. No such behavior was observed in the dog toxicity study, but whether intrathecal oxytocin would induce itching in humans is unknown.

**Physiological Effects of Intrathecal Oxytocin**

Changes in blood pressure and heart rate were suggested in the small dose-ranging study and in heart rate were confirmed in the repeated bolus study in dogs. The time of peak effect in these changes coincided with the time of peak oxytocin concentration in plasma, suggestive of a systemic effect. Bolus intravenous doses of 2 to 10 U (3.6 to 18 μg) oxytocin cause transient hypotension in women at cesarean delivery, and it is conceivable that the numerical reduction in blood pressure after intrathecal injection of 18 μg oxytocin in the dose-ranging study reflected a similar action. In contrast, the peak plasma concentrations of 20 to 30 μM far exceed the affinity of oxytocin at vasopressin V1a receptors, which produce vasoconstriction and, with sustained stimulation, hyponatremia. Severe hypertension or hyponatremia were not observed in any animal at any dose, and the study was not adequately powered to observe smaller changes which might be clinically relevant in some patients, so blood pressure and serum sodium should be carefully monitored in clinical investigations of intrathecal oxytocin. The reduction in heart rate with intrathecal oxytocin dosing was more clearly evident in these dogs, which could reflect enhanced baroreflex actions of oxytocin on vasopressin or oxytocin. As with blood pressure and serum sodium, heart rate should be closely monitored in the clinical introduction of intrathecal oxytocin.

**Limitations of Preclinical Toxicity Assessment**

As reviewed above, the current study represents a robust assessment of potential toxicity defining the lack of effect of doses 22 to 66 times those to be used in humans and of multiple versus a single administration. Nevertheless, it is important to recognize the limitations of preclinical toxicity screening such as in the current study. For practical and ethical

### Table 2. Individual Histology Spinal Cord Scores in Dogs

<table>
<thead>
<tr>
<th>Dog</th>
<th>Drug</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>543 2774, female</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.75</td>
</tr>
<tr>
<td>502 8604, male</td>
<td>Oxytocin</td>
<td>1.00</td>
<td>1.25</td>
<td>0.75</td>
<td>0.75</td>
<td>3.75</td>
</tr>
<tr>
<td>542 9935, female</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>1.25</td>
<td>0.75</td>
<td>1.00</td>
<td>3.75</td>
</tr>
<tr>
<td>503 7565, male</td>
<td>Oxytocin</td>
<td>1.00</td>
<td>2.00</td>
<td>1.25</td>
<td>1.00</td>
<td>5.25</td>
</tr>
<tr>
<td>501 8501, male</td>
<td>Oxytocin</td>
<td>0.75</td>
<td>1.00</td>
<td>2.00</td>
<td>2.25</td>
<td>6.00</td>
</tr>
<tr>
<td>543 0194, female</td>
<td>Oxytocin</td>
<td>3.00</td>
<td>2.00</td>
<td>2.25</td>
<td>3.00</td>
<td>10.25</td>
</tr>
<tr>
<td>543 4297, female</td>
<td>Saline</td>
<td>0.00</td>
<td>0.00</td>
<td>0.75</td>
<td>0.75</td>
<td>1.50</td>
</tr>
<tr>
<td>501 5219, male</td>
<td>Saline</td>
<td>0.75</td>
<td>0.75</td>
<td>0.75</td>
<td>1.00</td>
<td>3.25</td>
</tr>
<tr>
<td>501 5014, male</td>
<td>Saline</td>
<td>0.75</td>
<td>0.00</td>
<td>1.00</td>
<td>1.00</td>
<td>2.75</td>
</tr>
<tr>
<td>502 9988, male</td>
<td>Saline</td>
<td>3.00</td>
<td>3.00</td>
<td>3.00</td>
<td>2.00</td>
<td>11.00</td>
</tr>
</tbody>
</table>

*P value (oxytocin vs. saline) 0.2381 0.2381 0.4571 0.4571 0.3048
(Mann–Whitney one tailed) U = 8.5 U = 8.0 U = 11.0 U = 11.5 U = 9.5*
reasons, studies are performed in a small number of animals, and even relatively common (30% incidence) catastrophic events cannot be observed with statistical certainty. Although this is counterbalanced to some degree by the large increase in dose and concentration beyond the planned clinical ones, it is still conceivable that local neurotoxicity could occur. There is also a large species difference in normal circulating oxytocin concentrations, with humans showing levels 1 to 5% of those in these dog studies,97 and it is conceivable that more pronounced systemic effects may occur clinically due to increased sensitivity in humans. Neither rat nor dog studies predicted severe nausea after intrathecal neostigmine in humans26,38 although in this case one could anticipate an emetogenic effect by cholinergic stimulation of the area postrema after cephalad spread. Oxytocin, in contrast, is not associated with nausea in the absence of its use for postpartum hemorrhage where other factors may be involved. Finally, laboratory and case reports suggest that oxytocin can prolong QT interval14,39 and this was not assessed in the current study. Whether intrathecal oxytocin alters QT interval deserves study.

Fig. 6. (A and B) Representative hematoxylin and eosin–stained section of D block of dogs receiving five repeated intrathecal injections of saline. (A) The dura is focally, mildly thickened adjacent to the catheter site (box, shown in higher magnification in B). The arachnoid has no inflammation, but has mild, multifocal fibrosis (arrows). There is no inflammation in spinal cord or nerve roots. (B) The region of dural thickening has fibroblast proliferation and macrophage infiltration on the inner surface of the dura (between arrows). (C and D) Representative hematoxylin and eosin–stained section of D block of dogs receiving five repeated intrathecal injections of oxytocin (550 μg/0.5 ml). The arachnoid has a diffuse, but sparse infiltrate of lymphocytes and plasma cells, predominantly perivascular (boxed area shown at higher magnification in D). There is no inflammation in spinal nerve roots or spinal cord. (D) Higher magnification of boxed area in C. There is a sparse chronic inflammation, predominantly perivascular (arrows). (E and F) Glial fibrillary acidic protein stains. Insets represent higher magnifications of indicated areas. (E) Saline–treated dog. (F) Oxytocin–treated dog. There is delicate astrocytic staining. No reactive astrocytes were noted after five daily intrathecal injections of either injectate. Magnification bars: A, C = 1 mm; B, D = 100 μm; E, F = 600 μm, insets = 100 μm.
Summary

Robust studies reported here in two species (rats and dog) do not show signs of neurotoxicity from intrathecal bolus dosing of oxytocin in concentrations up to 1,100 μg/ml and up to total doses of 11 μg in the rat and 550 μg in the dog. There is a suggestion that the highest dose of intrathecal oxytocin in dogs might decrease heart rate, but does not alter serum sodium concentration. These results resulted in Investigation New Drug approval from the Food and Drug Administration to begin clinical investigation of intrathecal oxytocin as a novel analgesic, and they guide the focus of safety assessments in those initial trials.

Acknowledgments

The authors thank the expert assistance of Chuanyao Tong, M.D., Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and Nicolle Tozier, B.S., and Mary Ceccolini, B.S., Department of Anesthesiology, University of California, San Diego, California.

Supported in part by grant GM048085 from the National Institutes of Health, Bethesda, Maryland.

Competing Interests

The authors declare no competing interests.

Correspondence

Address correspondence to Dr. Eisenach: Department of Anesthesiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1009. jimeisenach@gmail.com. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

References


Fig. 7. Representative Luxol fast blue–stained sections of C blocks. (A and B) Saline-injected animal; (C and D) oxytocin-injected animal. The boxes in A and C indicate the regions shown at higher magnification in B and D. There is no evidence of demyelination. The larger unstained areas in B and D are neurons (n) and blood vessels (bv). Magnification bars: A, C = 600 μ; B, D = 100 μ.
PVN electrical stimulation prolongs withdrawal latencies and releases oxytocin in cerebrospinal fluid, plasma, and spinal cord tissue in intact and neuropathic rats. Pain 2008; 140:265–73


